SCHEMBL26440334

SCHEMBL26440334

COC(=O)[C@@H]1CN(Cc2ccccc2)C(Cc2cccc(C(F)(F)F)c2)=N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.45
S1PR1 P21453 2/20 0.44
S1PR5 Q9H228 2/20 0.44
GRK5 P34947 1/20 0.44
CDK8 P49336 1/20 0.44
PDGFRA P16234 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
KCNJ6 P48051 3/20 0.42
KCNJ5 P48544 3/20 0.42
KCNJ3 P48549 3/20 0.42
TEAD1 P28347 1/20 0.42
POLB P06746 1/20 0.41
FAAH O00519 1/20 0.41
NTSR1 P30989 1/20 0.41
UBE2M P61081 1/20 0.41
DCUN1D1 Q96GG9 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30069842 0.83 DRD4 (0.40) SIGMAR1KMT2AMEN1
SCHEMBL26440261 0.83 DRD4 (0.40) SIGMAR1KMT2AMEN1
SCHEMBL30069736 0.83 S1PR1 (0.39) SIGMAR1S1PR1S1PR5GRK5CDK8
SCHEMBL26440123 0.83 S1PR1 (0.39) SIGMAR1S1PR1S1PR5GRK5CDK8
SCHEMBL26440108 0.74 HTT (0.42) KMT2AMEN1POLBALDH1A1SMN1; SMN2
SCHEMBL30069844 0.74 HTT (0.42) KMT2AMEN1POLBALDH1A1SMN1; SMN2
SCHEMBL26440184 0.74 POLB (0.43) KMT2APOLBSMN1; SMN2
SCHEMBL30069894 0.74 SCD (0.43) KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL4795172 0.74 SCD (0.43) KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL29505002 0.71 TEAD1 (0.63) KMT2ATEAD1POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131899-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
US-20230131899-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
US-20230131899-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
EP-4087560-A2 INHIBITORS OF MICROBIALLY INDUCED AMYLOID Axial Therapeutics, Inc. (US) 2022-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131899-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP SIGMAR1 2357/4885S1PR1 3668/4885S1PR5 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.